Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of prescription medicines. The company operates primarily within the pharmaceutical and biotechnology industries, with a strong emphasis on science-driven innovation. Its core therapeutic areas include oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and vaccines and immune therapies. AstraZeneca’s revenues are primarily generated from patented specialty medicines and biologics sold to healthcare systems, hospitals, and pharmacies worldwide.
Founded in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group, AstraZeneca has evolved into one of the world’s largest research-based pharmaceutical companies. Over the past decade, the company has repositioned its portfolio toward high-growth, specialty care areas—particularly oncology and biologics—supported by significant investment in R&D and strategic acquisitions. Its differentiated positioning is driven by a robust late-stage pipeline, strong biologics capabilities, and a growing presence in precision medicine.
Business Operations
AstraZeneca reports its operations across three primary business segments: Oncology, BioPharmaceuticals, and Rare Disease. Oncology is the company’s largest revenue driver, encompassing treatments for lung, breast, ovarian, prostate, and hematologic cancers. BioPharmaceuticals includes the CVRM and Respiratory & Immunology franchises, delivering therapies for chronic diseases such as diabetes, heart failure, asthma, and autoimmune disorders. The Rare Disease segment, largely built around the integration of Alexion Pharmaceuticals, focuses on complement-mediated and metabolic disorders.
The company operates a fully integrated global model, spanning drug discovery, clinical development, manufacturing, and commercialization. AstraZeneca controls extensive biologics manufacturing assets, advanced small-molecule platforms, and antibody engineering technologies. It maintains strategic partnerships with academic institutions and biopharmaceutical companies and operates key subsidiaries including Alexion Pharmaceuticals, MedImmune (biologics R&D legacy operations), and multiple country-level commercial entities.
Strategic Position & Investments
AstraZeneca’s strategy centers on accelerating growth through innovation, targeted acquisitions, and expansion in high-unmet-need therapeutic areas. A defining investment was the acquisition of Alexion Pharmaceuticals, which significantly expanded the company’s presence in rare diseases and biologics. The company continues to allocate substantial capital to R&D, consistently ranking among the highest pharmaceutical spenders globally in research investment.
Emerging focus areas include cell and gene therapies, next-generation biologics, antibody-drug conjugates, and data-driven drug development using artificial intelligence. AstraZeneca has also made minority investments and entered licensing agreements to strengthen its oncology pipeline and vaccine platforms. Its long-term strategy emphasizes sustainable growth, scientific leadership, and expansion in emerging healthcare markets.
Geographic Footprint
AstraZeneca is headquartered in Cambridge, United Kingdom, with a global operational footprint spanning more than 100 countries. Its major markets include North America, Europe, Asia-Pacific, China, Latin America, and Middle East & Africa, with the United States representing its single largest revenue-generating market.
The company maintains significant R&D centers in the United Kingdom, United States, Sweden, and China, alongside manufacturing facilities across Europe, North America, and Asia. AstraZeneca has made long-term investments in China, treating it as a strategic growth market with localized R&D, manufacturing, and commercial operations, reflecting its broader commitment to global healthcare access and regional innovation.
Leadership & Governance
AstraZeneca is led by an experienced executive team with a stated focus on science-led growth, patient-centric innovation, and long-term value creation. The leadership philosophy emphasizes rigorous governance, ethical standards, and sustainable business practices aligned with public health priorities.
Key executives include:
- Pascal Soriot – Chief Executive Officer
- Aradhana Sarin – Chief Financial Officer
- Susan Galbraith – Executive Vice President, Oncology R&D
- Mene Pangalos – Executive Vice President, BioPharmaceuticals R&D
- Pam Cheng – Executive Vice President, Operations & IT
- Dave Smoley – Executive Vice President, Commercial Operations